CENPF

Across TCGA pan-cancer cohorts, CENPF mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CENPF data layer compared with 29 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CENPF mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CENPF expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where CENPF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.684	0.900	.003	24	view →
CCRCC	OS	Median	III,IV	0.982	0.578	.015	6	view →
LUAD	OS	Quartile	II,III,IV	0.513	0.881	.019	4	view →
LSCC	DFS	Quartile	All	0.733	0.207	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CENPF–PDAC (DFS)

Open the PDAC breakdown →